Therapeutic targets in hypertension: is there a place for antagonists of the most potent vasoconstrictors? (Q37082781)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18269342%20AND%20SRC:MED&resulttype=core&format=json

2 January 2020

review article

1 reference

title

Therapeutic targets in hypertension: is there a place for antagonists of the most potent vasoconstrictors? (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18269342%20AND%20SRC:MED&resulttype=core&format=json

2 January 2020

main subject

arterial hypertension

0 references

author

Fernando Silva Carneiro

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18269342%20AND%20SRC:MED&resulttype=core&format=json

2 January 2020

Rita C. Tostes

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18269342%20AND%20SRC:MED&resulttype=core&format=json

2 January 2020

author name string

Fernanda R C Giachini

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18269342%20AND%20SRC:MED&resulttype=core&format=json

2 January 2020

Glaucia E Callera

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18269342%20AND%20SRC:MED&resulttype=core&format=json

2 January 2020

R Clinton Webb

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18269342%20AND%20SRC:MED&resulttype=core&format=json

2 January 2020

language of work or name

English

0 references

publication date

1 March 2008

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18269342%20AND%20SRC:MED&resulttype=core&format=json

Expert Opinion on Therapeutic Targets

2 January 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18269342%20AND%20SRC:MED&resulttype=core&format=json

2 January 2020

volume

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18269342%20AND%20SRC:MED&resulttype=core&format=json

2 January 2020

issue

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18269342%20AND%20SRC:MED&resulttype=core&format=json

2 January 2020

page(s)

327-339

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18269342%20AND%20SRC:MED&resulttype=core&format=json

A novel potent vasoconstrictor peptide produced by vascular endothelial cells

2 January 2020

cites work

1 reference

https://api.crossref.org/works/10.1517%2F14728222.12.3.327

Isoforms of endothelin-converting enzyme: why and where?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.12.3.327

International Union of Pharmacology. XXIX. Update on endothelin receptor nomenclature

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.12.3.327

Function of the endothelin(B) receptor in cardiovascular physiology and pathophysiology

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.12.3.327

Deletion of Endothelial Cell Endothelin B Receptors Does Not Affect Blood Pressure or Sensitivity to Salt

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.12.3.327

Vascular endothelin in hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.12.3.327

Endothelin receptor antagonists: another potential alternative for cardiovascular diseases.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.12.3.327

Endothelin-converting enzyme inhibitors: current status and perspectives.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.12.3.327

Angiotensin converting enzyme inhibition modulates endogenous endothelin in chronic canine thoracic inferior vena caval constriction

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.12.3.327

Differential effects of angiotensin II versus endothelin-1 inhibitions in hypertrophic left ventricular myocardium during transition to heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.12.3.327

Endothelin receptor blockade improves endothelial function in atherosclerotic patients on angiotensin converting enzyme inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.12.3.327

Effects of the 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors, atorvastatin and simvastatin, on the expression of endothelin-1 and endothelial nitric oxide synthase in vascular endothelial cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.12.3.327

Inhibitory effects of PPAR-gamma on endothelin-1-induced inflammatory pathways in vascular smooth muscle cells from normotensive and hypertensive rats.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.12.3.327

Antisense homology box-derived peptides represent a new class of endothelin receptor inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.12.3.327

A sensitive radioimmunoassay measuring endothelin-like immunoreactivity in human plasma: comparison of levels in patients with essential hypertension and normotensive control subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.12.3.327

Role of endothelin in human hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.12.3.327

Direct and sympathetically mediated venoconstriction in essential hypertension. Enhanced responses to endothelin-1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.12.3.327

Endothelin-1-induced vasoconstriction in humans. Reversal by calcium channel blockade but not by nitrovasodilators or endothelium-derived relaxing factor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.12.3.327

Role of endothelins in animal models of hypertension: focus on cardiovascular protection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.12.3.327

Endothelin, sex and hypertension.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.12.3.327

Endothelium-restricted overexpression of human endothelin-1 causes vascular remodeling and endothelial dysfunction

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.12.3.327

ETA receptor mediates altered leukocyte-endothelial cell interaction and adhesion molecules expression in DOCA-salt rats.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.12.3.327

Endothelin-1 increases vascular superoxide via endothelin(A)-NADPH oxidase pathway in low-renin hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.12.3.327

ETA receptor blockade decreases vascular superoxide generation in DOCA-salt hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.12.3.327

Endothelin-1-induced oxidative stress in DOCA-salt hypertension involves NADPH-oxidase-independent mechanisms.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.12.3.327

Bosentan for the prevention of overcirculation-induced experimental pulmonary arterial hypertension.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.12.3.327

The effect of an endothelin-receptor antagonist, bosentan, on blood pressure in patients with essential hypertension. Bosentan Hypertension Investigators

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.12.3.327

Ethnic differences in the vasoconstrictor activity of endogenous endothelin-1 in hypertensive patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.12.3.327

Enhanced vascular activity of endogenous endothelin-1 in obese hypertensive patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.12.3.327

The caudal neurosecretory system. A critical evaluation of the two-hormone hypothesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.12.3.327

Urotensin II: a somatostatin-like peptide in the caudal neurosecretory system of fishes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.12.3.327

Translational medicine in fish-derived peptides: from fish endocrinology to human physiology and diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.12.3.327

Cloning of the cDNA encoding the urotensin II precursor in frog and human reveals intense expression of the urotensin II gene in motoneurons of the spinal cord

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.12.3.327

Urotensin-II-converting enzyme activity of furin and trypsin in human cells in vitro.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.12.3.327

Human urotensin-II is a potent vasoconstrictor and agonist for the orphan receptor GPR14

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.12.3.327

Identification of urotensin II as the endogenous ligand for the orphan G-protein-coupled receptor GPR14

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.12.3.327

International Union of Pharmacology. XLVI. G protein-coupled receptor list.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.12.3.327

Urotensin II-induced hypotensive responses in Wistar-Kyoto (Wky) and spontaneously hypertensive (Shr) rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.12.3.327

Human urotensin-II is an endothelium-dependent vasodilator in rat small arteries

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.12.3.327

Cardiovascular effects of urotensin II in anesthetized and pithed rats.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.12.3.327

The role of urotensin II in cardiovascular and renal physiology and diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.12.3.327

Depressor and regionally-selective vasodilator effects of human and rat urotensin II in conscious rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.12.3.327

Angiotensin II and angiotensin II receptor blocker modulate the arrhythmogenic activity of pulmonary veins

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.12.3.327

Cellular distribution of GPR14 and the positive inotropic role of urotensin II in the myocardium in adult rat.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.12.3.327

Urotensin-II receptor antagonists.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.12.3.327

Human urotensin II-induced aorta ring contractions are mediated by protein kinase C, tyrosine kinases and Rho-kinase: inhibition by somatostatin receptor antagonists

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.12.3.327

Differential agonistic and antagonistic effects of the urotensin-II ligand SB-710411 at rodent and primate UT receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.12.3.327

The neuromedin B receptor antagonist, BIM-23127, is a potent antagonist at human and rat urotensin-II receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.12.3.327

A new ligand for the urotensin II receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.12.3.327

Urantide: an ultrapotent urotensin II antagonist peptide in the rat aorta

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.12.3.327

Urantide mimics urotensin-II induced calcium release in cells expressing recombinant UT receptors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.12.3.327

The peptidic urotensin-II receptor ligand GSK248451 possesses less intrinsic activity than the low-efficacy partial agonists SB-710411 and urantide in native mammalian tissues and recombinant cell systems

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.12.3.327

Urotensin II evokes potent vasoconstriction in humans in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.12.3.327

High plasma concentrations of human urotensin II do not alter local or systemic hemodynamics in man

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.12.3.327

Effect of exogenous urotensin-II on vascular tone in skin microcirculation of patients with essential hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.12.3.327

Co-expression of urotensin II and its receptor (GPR14) in human cardiovascular and renal tissues

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.12.3.327

Exercise urotensin II dynamics in myocardial infarction survivors with and without hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.12.3.327

A Comparison of Cerebrospinal Fluid and Plasma Urotensin II Concentrations in Normotensive and Hypertensive Patients Undergoing Urological Surgery During Spinal Anesthesia: A Pilot Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.12.3.327

Increased human urotensin II levels are correlated with carotid atherosclerosis in essential hypertension.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.12.3.327

Human urotensin II accelerates foam cell formation in human monocyte-derived macrophages

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.12.3.327

Flow-induced pressure differentially regulates endothelin-1, urotensin II, adrenomedullin, and relaxin in pulmonary vascular endothelium.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.12.3.327

Central cardiovascular action of urotensin II in spontaneously hypertensive rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.12.3.327

Human urotensin II-induced contraction and arterial smooth muscle cell proliferation are mediated by RhoA and Rho-kinase

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.12.3.327

Synergistic effect of urotensin II with serotonin on vascular smooth muscle cell proliferation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.12.3.327

Synergistic effect of urotensin II with mildly oxidized LDL on DNA synthesis in vascular smooth muscle cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.12.3.327

Cardiovascular role of urotensin II: effect of chronic infusion in the rat.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.12.3.327

Direct actions of urotensin II on the heart: implications for cardiac fibrosis and hypertrophy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.12.3.327

A role for urotensin II in restenosis following balloon angioplasty: use of a selective UT receptor blocker

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.12.3.327

Human urotensin II is a novel activator of NADPH oxidase in human pulmonary artery smooth muscle cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.12.3.327

Urotensin-II-mediated cardiomyocyte hypertrophy: effect of receptor antagonism and role of inflammatory mediators

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.12.3.327

Haplotypes in the urotensin II gene and urotensin II receptor gene are associated with insulin resistance and impaired glucose tolerance

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.12.3.327

Congestive heart failure and expression of myocardial urotensin II.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.12.3.327

Orphan-receptor ligand human urotensin II: receptor localization in human tissues and comparison of vasoconstrictor responses with endothelin-1

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.12.3.327

Renal and vascular actions of urotensin II

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.12.3.327

Genetic variations at urotensin II and urotensin II receptor genes and risk of type 2 diabetes mellitus in Japanese

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.12.3.327

Structure-activity relationship study on human urotensin II

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.12.3.327

Architecture of the Human Urotensin II Receptor: Comparison of the Binding Domains of Peptide and Non-Peptide Urotensin II Agonists

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.12.3.327

Urotensin II and Biomarkers of Endothelial Activation and Atherosclerosis in End-Stage Renal Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.12.3.327